Shopping Cart 0
Cart Subtotal
AED 0

Chugai Pharmaceutical Co Ltd (4519) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
AED 918

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
AED 1835

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
AED 2753

Details

Summary

Chugai Pharmaceutical Co Ltd (Chugai) is a subsidiary of Hoffmann-La Roche Ltd, which focuses on the research, development, manufacture, commercialization, import and export of the biopharmaceuticals and therapeutic antibodies. The company offers products for the treatment of cancer; bone and joint diseases; renal diseases; immunology and infectious diseases and others. It also offers drugs to aid kidney, liver and other organ transplantations. It also has a range of product candidates in its pipeline. Operating through its network of subsidiaries, the company offers its pharmaceutical products in overseas markets including North America, Europe and Asia. Chugai is headquartered in Tokyo, Japan.

Chugai Pharmaceutical Co Ltd (4519)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 6

List of Figures 6

Chugai Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

Chugai Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8

Chugai Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

Chugai Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10

Chugai Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12

Chugai Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deal Details 15

Partnerships 15

Helsinn Enters into Licensing Agreement with Chugai Pharma for Netupitant-Palonosetron Fixed-Dose Combination 15

Anaeropharma Science Enters into Research Agreement with Chugai Pharma 16

Chugai Pharma Enters into Research Agreement with National Cancer Center Japan 17

Astellas Pharm, Kyowa Hakko Kirin, Daiichi Sankyo, Eisai, Ono Pharma and Chugai Pharma to Enter into Agreemet with Four Research Institutions 18

Chugai Pharmaceutical Enters into Agreement with Osaka University 20

Chugai Pharma Enters Into Co-Development Agreement With Nippon Shinyaku For GA101 21

Licensing Agreements 22

Eli Lilly to Enter into Licensing Agreement with Chugai Pharma 22

Chugai Pharma Enters into Licensing Agreement with Roche 23

JW Pharma Enters into Licensing Agreement with Chugai Pharma 24

Chugai Pharma Enters into Licensing Agreement with SBI Pharma 25

Berlin-Chemie Enters into Licensing Agreement with Chugai Pharma 26

Galderma Pharma Enters into Licensing Agreement with Chugai Pharma 27

Roche Enters into Licensing Agreement with Chugai Pharma for Recycling Antibody SA237 28

Chugai Pharma Enters into Licensing Agreement with Two Cells 29

BioMarin Pharma Enters into Sub-license Agreement with Chugai Pharma 30

Kowa Company Enters into Licensing Agreement with Chugai Pharmaceutical 31

Roche Amends Licensing Agreement with Chugai Pharma 32

PharmaMar Enters into Licensing Agreement with Chugai Pharma for Aplidin 33

Chugai Pharma Enters into Licensing Agreement with Roche 34

Chugai Pharma Enters Into Licensing Agreement With Debiopharm Group For FF284 35

Chugai Pharma Expands Licensing Agreement with Kowa for DEBERZA 36

Maruho Enters into Licensing Agreement with Chugai Pharma 37

EpiVax Enters into Licensing Agreement with Chugai Pharma 38

Helsinn Enters Into Licensing Agreement With Chugai Pharma Marketing For Anamorelin 39

Chugai Pharma Extends Licensing Agreement With Genedata For Genedata Expressionist Software 40

Asset Transactions 41

Taiyo Pharma to Acquire Product Rights from Chugai Pharma and Roche 41

Eisai Acquires Rights to Manufacture Active Pharmaceutical Ingredients in Japan from Chugai Pharma and F. Hoffman-La Roche 42

Acquisition 43

Roche May Acquire 40% Stake in Chugai Pharma 43

Chugai Pharmaceutical Co Ltd-Key Competitors 44

Chugai Pharmaceutical Co Ltd-Key Employees 45

Chugai Pharmaceutical Co Ltd-Locations And Subsidiaries 47

Head Office 47

Other Locations & Subsidiaries 47

Joint Venture 49

Recent Developments 50

Strategy And Business Planning 50

Jul 27, 2018: Chugai Pharmaceutical to expand Singaporean research subsidiary 50

Jul 26, 2018: Chugai Pharmaceutical announce construction of a new synthetic research building to enhance process development for small and middle molecule APls 51

Jan 27, 2017: Aiming to Provide Solutions that Meet Changes of Regional Healthcare Services 52

Financial Announcements 53

Oct 24, 2018: Chugai Pharmaceutical: FY2018 3Q financial results 53

Corporate Communications 54

Oct 12, 2018: Chugai releases disease awareness anime about Rheumatoid Arthritis in multiple languages emphasizing importance of early detection/treatment and care by specialists 54

Jul 26, 2018: Chugai Pharmaceutical announces organizational and personnel changes 55

Dec 12, 2017: Notice on Change of Chief Executive Officer 56

Legal and Regulatory 57

Aug 29, 2018: Chugai obtains Platinum Kurumin certification from the minister of health, labour and welfare as a company supporting childrearing 57

Government and Public Interest 58

Mar 30, 2017: Chugai-ASTAR Joint Development Project for Anti-Dengue Virus Antibody Selected as Grant Recipient by the GHIT Fund 58

Product News 59

11/02/2017: Health Canada Approves ACTEMRA (tocilizumab) for Canadians Living with Giant Cell Arteritis 59

10/13/2017: CHMP recommends EU approval of Roche's Alecensa (alectinib) as a first-line treatment for people with ALK-positive NSCLC 60

09/22/2017: Roche Receives European Approval for Actemra /RoActemra in Giant Cell Arteritis 61

08/30/2017: FDA approves Roche's Actemra/RoActemra (tocilizumab) for the treatment of CAR T cell-induced cytokine release syndrome 62

08/25/2017: Approval of Actemra for Additional Indications of Takayasu Arteritis and Giant Cell Arteritis, Both are Designated Intractable Diseases 63

08/10/2017: Announcement of Commencement of Arbitration against Chugai 64

06/26/2017: Approval of Additional Dosage for Actemra Subcutaneous Injection Reducing Dose Interval to One Week in Patients with Rheumatoid Arthritis Who Inadequately Respond to Bi-weekly Dose 65

05/22/2017: FDA approves first drug to specifically treat giant cell arteritis 66

04/04/2017: NICE Terminates Appraisal for Alectinib in Previously Treated ALK-positive Advanced NSCLC 67

02/27/2017: Chugai's ALK Inhibitor Alecensa Approved in Taiwan 68

02/21/2017: Roche receives EU approval of Alecensa (alectinib) for people with previously treated ALK-positive non-small cell lung cancer 69

Product Approvals 71

Mar 22, 2018: New Drug Application of Eldecalcitol, an Active Vitamin D3 Derivative, for the Treatment of Osteoporosis Accepted in China 71

Sep 01, 2017: Roche and MHRA to make treatment available for those newly diagnosed with a rare type of lung cancer in the UK before anywhere else in Europe 72

May 08, 2017: Roche's Alecensa Rejects For Use Within NHS Scotland 73

Jan 23, 2017: FDA Grants Priority Review For Genentech's Actemra (Tocilizumab) Supplemental Biologics License Application For Giant Cell Arteritis, a Form of Vasculitis 74

Clinical Trials 75

Nov 06, 2017: Eldecalcitol, an Active Vitamin D3 Derivative, Increases Bone Mineral Density of Osteoporosis Patients in Chinese Phase III Study 75

Oct 05, 2017: Chugais Bispecific Antibody ERY974 Results of Preclinical Study Published in Science Translational Medicine 76

Sep 06, 2017: Roche presents data from global phase III study showing significant clinical benefit of Alecensa (alectinib) in later-line advanced ALK-positive lung cancer 77

Aug 09, 2017: Genentech Completes Phase III Enrollment for Study of Actemra in Systemic Sclerosis 78

Aug 02, 2017: FDA Grants Genentech's Alecensa Priority Review for Initial Treatment of People with ALK-Positive Lung Cancer 79

Jul 26, 2017: Positive Phase III Results of Genentech's Actemra (Tocilizumab) for the Treatment of Giant Cell Arteritis Published in New England Journal of Medicine 81

Jul 25, 2017: Galderma Announces Enrollment of First Patient in Phase IIb Nemolizumab Trial in Atopic Dermatitis 83

Jul 21, 2017: Roche Gains Positive CHMP Opinion for Actemra / Roactemra in Giant Cell Arteritis 84

Jun 06, 2017: Alectinib potential new standard of care for ALK-positive non-small lung cancer 85

Jun 05, 2017: Phase III study showed Roche's Alecensa (alectinib) reduced the risk of disease progression or death by more than half versus crizotinib as first-line treatment in a specific type of lung cancer 86

May 11, 2017: Results of the J-ALEX Study for Chugais Alecensa are Published in The Lancet Online 88

Apr 10, 2017: Phase III study shows Roche's Alecensa was superior to crizotinib in a specific type of lung cancer 89

Apr 03, 2017: Phase III ALUR study supports the use of Roche's Alecensa for people with advanced ALK-positive lung cancer 90

Mar 02, 2017: Chugai's Anti-IL-31 Receptor A Humanized Monoclonal Antibody nemolizumab (CIM331) Global Phase II Study Data Published in The New England Journal of Medicine Online 92

Feb 08, 2017: Roche's Alecensa (alectinib) approved in Switzerland for people with a specific type of lung cancer 93

Other Significant Developments 95

Oct 17, 2018: F. Hoffmann-La Roche announces third quarter sales 2018 95

Oct 01, 2018: Chugai Redesigns Corporate Website 96

Apr 04, 2017: A First Approach in the Japanese Pharmaceutical Industry Starting a Trial of a Drug Adherence Support App Using Multidisciplinary SNS for Outpatient Cancer Treatment 97

Appendix 98

Methodology 98

About GlobalData 98

Contact Us 98

Disclaimer 98


List Of Figure

List of Figures

Chugai Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Chugai Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Chugai Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Chugai Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Chugai Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

Chugai Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 8

Chugai Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

Chugai Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10


List Of Table

List of Tables

Chugai Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Chugai Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

Chugai Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8

Chugai Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

Chugai Pharmaceutical Co Ltd, Deals By Therapy Area, 2012 to YTD 2018 10

Chugai Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12

Helsinn Enters into Licensing Agreement with Chugai Pharma for Netupitant-Palonosetron Fixed-Dose Combination 15

Anaeropharma Science Enters into Research Agreement with Chugai Pharma 16

Chugai Pharma Enters into Research Agreement with National Cancer Center Japan 17

Astellas Pharm, Kyowa Hakko Kirin, Daiichi Sankyo, Eisai, Ono Pharma and Chugai Pharma to Enter into Agreemet with Four Research Institutions 18

Chugai Pharmaceutical Enters into Agreement with Osaka University 20

Chugai Pharma Enters Into Co-Development Agreement With Nippon Shinyaku For GA101 21

Eli Lilly to Enter into Licensing Agreement with Chugai Pharma 22

Chugai Pharma Enters into Licensing Agreement with Roche 23

JW Pharma Enters into Licensing Agreement with Chugai Pharma 24

Chugai Pharma Enters into Licensing Agreement with SBI Pharma 25

Berlin-Chemie Enters into Licensing Agreement with Chugai Pharma 26

Galderma Pharma Enters into Licensing Agreement with Chugai Pharma 27

Roche Enters into Licensing Agreement with Chugai Pharma for Recycling Antibody SA237 28

Chugai Pharma Enters into Licensing Agreement with Two Cells 29

BioMarin Pharma Enters into Sub-license Agreement with Chugai Pharma 30

Kowa Company Enters into Licensing Agreement with Chugai Pharmaceutical 31

Roche Amends Licensing Agreement with Chugai Pharma 32

PharmaMar Enters into Licensing Agreement with Chugai Pharma for Aplidin 33

Chugai Pharma Enters into Licensing Agreement with Roche 34

Chugai Pharma Enters Into Licensing Agreement With Debiopharm Group For FF284 35

Chugai Pharma Expands Licensing Agreement with Kowa for DEBERZA 36

Maruho Enters into Licensing Agreement with Chugai Pharma 37

EpiVax Enters into Licensing Agreement with Chugai Pharma 38

Helsinn Enters Into Licensing Agreement With Chugai Pharma Marketing For Anamorelin 39

Chugai Pharma Extends Licensing Agreement With Genedata For Genedata Expressionist Software 40

Taiyo Pharma to Acquire Product Rights from Chugai Pharma and Roche 41

Eisai Acquires Rights to Manufacture Active Pharmaceutical Ingredients in Japan from Chugai Pharma and F. Hoffman-La Roche 42

Roche May Acquire 40% Stake in Chugai Pharma 43

Chugai Pharmaceutical Co Ltd, Key Competitors 44

Chugai Pharmaceutical Co Ltd, Key Employees 45

Chugai Pharmaceutical Co Ltd, Other Locations 47

Chugai Pharmaceutical Co Ltd, Subsidiaries 48

Chugai Pharmaceutical Co Ltd, Joint Venture 49

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Chugai Pharmaceutical Co Ltd, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

Chugai Pharmaceutical Co Ltd (Chugai) is a subsidiary of Hoffmann-La Roche Ltd, which focuses on the research, development, manufacture, commercialization, import and export of the biopharmaceuticals and therapeutic antibodies. The company offers products for the treatment of cancer; bone and joint diseases; renal diseases; immunology and infectious diseases and others. It also offers drugs to aid kidney, liver and other organ transplantations. It also has a range of product candidates in its pipeline. Operating through its network of subsidiaries, the company offers its pharmaceutical products in overseas markets including North America, Europe and Asia. Chugai is headquartered in Tokyo, Japan.

Chugai Pharmaceutical Co Ltd (4519)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 6

List of Figures 6

Chugai Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

Chugai Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8

Chugai Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

Chugai Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10

Chugai Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12

Chugai Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deal Details 15

Partnerships 15

Helsinn Enters into Licensing Agreement with Chugai Pharma for Netupitant-Palonosetron Fixed-Dose Combination 15

Anaeropharma Science Enters into Research Agreement with Chugai Pharma 16

Chugai Pharma Enters into Research Agreement with National Cancer Center Japan 17

Astellas Pharm, Kyowa Hakko Kirin, Daiichi Sankyo, Eisai, Ono Pharma and Chugai Pharma to Enter into Agreemet with Four Research Institutions 18

Chugai Pharmaceutical Enters into Agreement with Osaka University 20

Chugai Pharma Enters Into Co-Development Agreement With Nippon Shinyaku For GA101 21

Licensing Agreements 22

Eli Lilly to Enter into Licensing Agreement with Chugai Pharma 22

Chugai Pharma Enters into Licensing Agreement with Roche 23

JW Pharma Enters into Licensing Agreement with Chugai Pharma 24

Chugai Pharma Enters into Licensing Agreement with SBI Pharma 25

Berlin-Chemie Enters into Licensing Agreement with Chugai Pharma 26

Galderma Pharma Enters into Licensing Agreement with Chugai Pharma 27

Roche Enters into Licensing Agreement with Chugai Pharma for Recycling Antibody SA237 28

Chugai Pharma Enters into Licensing Agreement with Two Cells 29

BioMarin Pharma Enters into Sub-license Agreement with Chugai Pharma 30

Kowa Company Enters into Licensing Agreement with Chugai Pharmaceutical 31

Roche Amends Licensing Agreement with Chugai Pharma 32

PharmaMar Enters into Licensing Agreement with Chugai Pharma for Aplidin 33

Chugai Pharma Enters into Licensing Agreement with Roche 34

Chugai Pharma Enters Into Licensing Agreement With Debiopharm Group For FF284 35

Chugai Pharma Expands Licensing Agreement with Kowa for DEBERZA 36

Maruho Enters into Licensing Agreement with Chugai Pharma 37

EpiVax Enters into Licensing Agreement with Chugai Pharma 38

Helsinn Enters Into Licensing Agreement With Chugai Pharma Marketing For Anamorelin 39

Chugai Pharma Extends Licensing Agreement With Genedata For Genedata Expressionist Software 40

Asset Transactions 41

Taiyo Pharma to Acquire Product Rights from Chugai Pharma and Roche 41

Eisai Acquires Rights to Manufacture Active Pharmaceutical Ingredients in Japan from Chugai Pharma and F. Hoffman-La Roche 42

Acquisition 43

Roche May Acquire 40% Stake in Chugai Pharma 43

Chugai Pharmaceutical Co Ltd-Key Competitors 44

Chugai Pharmaceutical Co Ltd-Key Employees 45

Chugai Pharmaceutical Co Ltd-Locations And Subsidiaries 47

Head Office 47

Other Locations & Subsidiaries 47

Joint Venture 49

Recent Developments 50

Strategy And Business Planning 50

Jul 27, 2018: Chugai Pharmaceutical to expand Singaporean research subsidiary 50

Jul 26, 2018: Chugai Pharmaceutical announce construction of a new synthetic research building to enhance process development for small and middle molecule APls 51

Jan 27, 2017: Aiming to Provide Solutions that Meet Changes of Regional Healthcare Services 52

Financial Announcements 53

Oct 24, 2018: Chugai Pharmaceutical: FY2018 3Q financial results 53

Corporate Communications 54

Oct 12, 2018: Chugai releases disease awareness anime about Rheumatoid Arthritis in multiple languages emphasizing importance of early detection/treatment and care by specialists 54

Jul 26, 2018: Chugai Pharmaceutical announces organizational and personnel changes 55

Dec 12, 2017: Notice on Change of Chief Executive Officer 56

Legal and Regulatory 57

Aug 29, 2018: Chugai obtains Platinum Kurumin certification from the minister of health, labour and welfare as a company supporting childrearing 57

Government and Public Interest 58

Mar 30, 2017: Chugai-ASTAR Joint Development Project for Anti-Dengue Virus Antibody Selected as Grant Recipient by the GHIT Fund 58

Product News 59

11/02/2017: Health Canada Approves ACTEMRA (tocilizumab) for Canadians Living with Giant Cell Arteritis 59

10/13/2017: CHMP recommends EU approval of Roche's Alecensa (alectinib) as a first-line treatment for people with ALK-positive NSCLC 60

09/22/2017: Roche Receives European Approval for Actemra /RoActemra in Giant Cell Arteritis 61

08/30/2017: FDA approves Roche's Actemra/RoActemra (tocilizumab) for the treatment of CAR T cell-induced cytokine release syndrome 62

08/25/2017: Approval of Actemra for Additional Indications of Takayasu Arteritis and Giant Cell Arteritis, Both are Designated Intractable Diseases 63

08/10/2017: Announcement of Commencement of Arbitration against Chugai 64

06/26/2017: Approval of Additional Dosage for Actemra Subcutaneous Injection Reducing Dose Interval to One Week in Patients with Rheumatoid Arthritis Who Inadequately Respond to Bi-weekly Dose 65

05/22/2017: FDA approves first drug to specifically treat giant cell arteritis 66

04/04/2017: NICE Terminates Appraisal for Alectinib in Previously Treated ALK-positive Advanced NSCLC 67

02/27/2017: Chugai's ALK Inhibitor Alecensa Approved in Taiwan 68

02/21/2017: Roche receives EU approval of Alecensa (alectinib) for people with previously treated ALK-positive non-small cell lung cancer 69

Product Approvals 71

Mar 22, 2018: New Drug Application of Eldecalcitol, an Active Vitamin D3 Derivative, for the Treatment of Osteoporosis Accepted in China 71

Sep 01, 2017: Roche and MHRA to make treatment available for those newly diagnosed with a rare type of lung cancer in the UK before anywhere else in Europe 72

May 08, 2017: Roche's Alecensa Rejects For Use Within NHS Scotland 73

Jan 23, 2017: FDA Grants Priority Review For Genentech's Actemra (Tocilizumab) Supplemental Biologics License Application For Giant Cell Arteritis, a Form of Vasculitis 74

Clinical Trials 75

Nov 06, 2017: Eldecalcitol, an Active Vitamin D3 Derivative, Increases Bone Mineral Density of Osteoporosis Patients in Chinese Phase III Study 75

Oct 05, 2017: Chugais Bispecific Antibody ERY974 Results of Preclinical Study Published in Science Translational Medicine 76

Sep 06, 2017: Roche presents data from global phase III study showing significant clinical benefit of Alecensa (alectinib) in later-line advanced ALK-positive lung cancer 77

Aug 09, 2017: Genentech Completes Phase III Enrollment for Study of Actemra in Systemic Sclerosis 78

Aug 02, 2017: FDA Grants Genentech's Alecensa Priority Review for Initial Treatment of People with ALK-Positive Lung Cancer 79

Jul 26, 2017: Positive Phase III Results of Genentech's Actemra (Tocilizumab) for the Treatment of Giant Cell Arteritis Published in New England Journal of Medicine 81

Jul 25, 2017: Galderma Announces Enrollment of First Patient in Phase IIb Nemolizumab Trial in Atopic Dermatitis 83

Jul 21, 2017: Roche Gains Positive CHMP Opinion for Actemra / Roactemra in Giant Cell Arteritis 84

Jun 06, 2017: Alectinib potential new standard of care for ALK-positive non-small lung cancer 85

Jun 05, 2017: Phase III study showed Roche's Alecensa (alectinib) reduced the risk of disease progression or death by more than half versus crizotinib as first-line treatment in a specific type of lung cancer 86

May 11, 2017: Results of the J-ALEX Study for Chugais Alecensa are Published in The Lancet Online 88

Apr 10, 2017: Phase III study shows Roche's Alecensa was superior to crizotinib in a specific type of lung cancer 89

Apr 03, 2017: Phase III ALUR study supports the use of Roche's Alecensa for people with advanced ALK-positive lung cancer 90

Mar 02, 2017: Chugai's Anti-IL-31 Receptor A Humanized Monoclonal Antibody nemolizumab (CIM331) Global Phase II Study Data Published in The New England Journal of Medicine Online 92

Feb 08, 2017: Roche's Alecensa (alectinib) approved in Switzerland for people with a specific type of lung cancer 93

Other Significant Developments 95

Oct 17, 2018: F. Hoffmann-La Roche announces third quarter sales 2018 95

Oct 01, 2018: Chugai Redesigns Corporate Website 96

Apr 04, 2017: A First Approach in the Japanese Pharmaceutical Industry Starting a Trial of a Drug Adherence Support App Using Multidisciplinary SNS for Outpatient Cancer Treatment 97

Appendix 98

Methodology 98

About GlobalData 98

Contact Us 98

Disclaimer 98


List Of Figure

List of Figures

Chugai Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Chugai Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Chugai Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Chugai Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Chugai Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

Chugai Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 8

Chugai Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

Chugai Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10


List Of Table

List of Tables

Chugai Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Chugai Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

Chugai Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8

Chugai Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

Chugai Pharmaceutical Co Ltd, Deals By Therapy Area, 2012 to YTD 2018 10

Chugai Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12

Helsinn Enters into Licensing Agreement with Chugai Pharma for Netupitant-Palonosetron Fixed-Dose Combination 15

Anaeropharma Science Enters into Research Agreement with Chugai Pharma 16

Chugai Pharma Enters into Research Agreement with National Cancer Center Japan 17

Astellas Pharm, Kyowa Hakko Kirin, Daiichi Sankyo, Eisai, Ono Pharma and Chugai Pharma to Enter into Agreemet with Four Research Institutions 18

Chugai Pharmaceutical Enters into Agreement with Osaka University 20

Chugai Pharma Enters Into Co-Development Agreement With Nippon Shinyaku For GA101 21

Eli Lilly to Enter into Licensing Agreement with Chugai Pharma 22

Chugai Pharma Enters into Licensing Agreement with Roche 23

JW Pharma Enters into Licensing Agreement with Chugai Pharma 24

Chugai Pharma Enters into Licensing Agreement with SBI Pharma 25

Berlin-Chemie Enters into Licensing Agreement with Chugai Pharma 26

Galderma Pharma Enters into Licensing Agreement with Chugai Pharma 27

Roche Enters into Licensing Agreement with Chugai Pharma for Recycling Antibody SA237 28

Chugai Pharma Enters into Licensing Agreement with Two Cells 29

BioMarin Pharma Enters into Sub-license Agreement with Chugai Pharma 30

Kowa Company Enters into Licensing Agreement with Chugai Pharmaceutical 31

Roche Amends Licensing Agreement with Chugai Pharma 32

PharmaMar Enters into Licensing Agreement with Chugai Pharma for Aplidin 33

Chugai Pharma Enters into Licensing Agreement with Roche 34

Chugai Pharma Enters Into Licensing Agreement With Debiopharm Group For FF284 35

Chugai Pharma Expands Licensing Agreement with Kowa for DEBERZA 36

Maruho Enters into Licensing Agreement with Chugai Pharma 37

EpiVax Enters into Licensing Agreement with Chugai Pharma 38

Helsinn Enters Into Licensing Agreement With Chugai Pharma Marketing For Anamorelin 39

Chugai Pharma Extends Licensing Agreement With Genedata For Genedata Expressionist Software 40

Taiyo Pharma to Acquire Product Rights from Chugai Pharma and Roche 41

Eisai Acquires Rights to Manufacture Active Pharmaceutical Ingredients in Japan from Chugai Pharma and F. Hoffman-La Roche 42

Roche May Acquire 40% Stake in Chugai Pharma 43

Chugai Pharmaceutical Co Ltd, Key Competitors 44

Chugai Pharmaceutical Co Ltd, Key Employees 45

Chugai Pharmaceutical Co Ltd, Other Locations 47

Chugai Pharmaceutical Co Ltd, Subsidiaries 48

Chugai Pharmaceutical Co Ltd, Joint Venture 49

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Chugai Pharmaceutical Co Ltd, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.